Compare AHMA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | MGNX |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.6M | 115.8M |
| IPO Year | N/A | 2013 |
| Metric | AHMA | MGNX |
|---|---|---|
| Price | $1.08 | $2.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 12-08-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.14 |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.06 | $0.99 |
| 52 Week High | $39.50 | $3.50 |
| Indicator | AHMA | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 20.75 | 52.74 |
| Support Level | N/A | $1.46 |
| Resistance Level | $9.75 | $3.50 |
| Average True Range (ATR) | 0.89 | 0.24 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 0.27 | 3.70 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.